News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sunovion Pharmaceuticals Inc.'s Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients With Schizophrenia


5/7/2012 9:13:47 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia. The FDA decision followed a review of the supplemental New Drug Application (sNDA), which was submitted in June 2011.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES